Rocuronium: Difference between revisions
| Line 39: | Line 39: | ||
==Sources== | ==Sources== | ||
Micromedex | |||
<references/> | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 07:01, 3 November 2014
General
- Type: Neuromuscular blocker, Non-Depolarizing, Fast Onset, Intermediate Lasting
- Dosage Forms: IV
- Common Trade Names: Zemuron
Adult Dosing
RSI is 0.6 to 1.2 mg/kg IV (actual body weight)
Pediatric Dosing
RSI is 0.6 to 1.2 mg/kg IV (actual body weight)
Special Populations
- Pregnancy Rating: C
- Lactation: Infant risk cannot be ruled out
- Renal Dosing (half life approximately 1 hour longer if renal transplant patient)
- Adult
- Pediatric
- Hepatic Dosing (half life approximately 3 hours longer with liver dysfunction)
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Anaphylaxis
Common
Cardiovascular: HTN (0.1% to 2%). Hypotension (0.1% to 2%). Tachycardia (1% to 5.3%) Dermatologic: Pain at injection site Respiratory: Increased pulmonary vascular resistance (24%)
Pharmacology
- Half-life: Variable by age, but anywhere from 30 minutes to 2 hours.
- Metabolism: Metabolite is 17-desacetyl-rocuronium
- Excretion: Primary route is fecal. Renal also.
- Mechanism of Action: Non-depolarizing neuromuscular blocking agent. Intermediate duration with dose dependant rapid to intermediate onset. Competes for cholinergic receptors at the motor end-plate. Acetylcholinesterase inhibitors like those found in organophosphates antagonize this action
See Also
Sources
Micromedex